• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名百岁COVID-19患者长期服用帕罗韦德的病例报告。

Prolonged course of Paxlovid administration in a centenarian with COVID-19: A case report.

作者信息

Zhang Yi-Xue, Tang Juan, Zhu Dan, Wu Chun-Yan, Liang Mei-Lan, Huang Yuan-Tao

机构信息

Department of Healthcare, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, Hainan Province, China.

Department of Healthcare, Hainan Chengmei Hospital, Haikou 570000, Hainan Province, China.

出版信息

World J Radiol. 2024 Sep 28;16(9):489-496. doi: 10.4329/wjr.v16.i9.489.

DOI:10.4329/wjr.v16.i9.489
PMID:39355387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11440271/
Abstract

BACKGROUND

According to the population statistics in 2023, there were 110000 people aged over 100 years in China, and the experience of using Paxlovid (nirmatrelvir/ritonavir) for centenarians is particularly valuable. This article reports our experience of using Paxlovid in a centenarian with the novel coronavirus disease 2019 (COVID-19) infection.

CASE SUMMARY

A 103-year-old female with mild COVID-19 and renal insufficiency was given sufficient Paxlovid for 2 days and a half dose for 3 days. During treatment, the patient was complicated with lung infection and heart failure, and nucleic acid remained positive. After expert consultation, a full dose of Paxlovid was given again on the 9th day of admission for 2 days and a half dose for 3 days. Meanwhile, anti-heart failure and antibiotics were administered; the heart failure and pulmonary infection were improved. Finally, on the 33 day of admission, nucleic acid turned negative, body temperature returned to normal, cough and sputum, fatigue, poor appetite and other symptoms basically improved. The patient was given Paxlovid nasal feeding for 2 courses without deterioration of liver and kidney function, diarrhea, nausea and vomiting, myalgia, chest tightness and other side effects, and was discharged from hospital with good recovery.

CONCLUSION

This case suggests that Paxlovid can be used cautiously in centenarians with renal insufficiency and two courses of treatment can be considered in patients with persistent positive nucleic acid.

摘要

背景

根据2023年人口统计数据,中国有11万100岁以上的老人,帕罗韦德(奈玛特韦/利托那韦)用于百岁老人的经验尤为宝贵。本文报告了我们在一名新型冠状病毒肺炎(COVID-19)感染的百岁老人中使用帕罗韦德的经验。

病例摘要

一名103岁患有轻度COVID-19且肾功能不全的女性,给予足量帕罗韦德2天,半量3天。治疗期间,患者并发肺部感染和心力衰竭,核酸仍为阳性。经专家会诊,入院第9天再次给予足量帕罗韦德2天,半量3天。同时给予抗心力衰竭和抗生素治疗;心力衰竭和肺部感染得到改善。最终,入院第33天,核酸转阴,体温恢复正常,咳嗽咳痰、乏力、食欲差等症状基本改善。患者给予帕罗韦德鼻饲2个疗程,未出现肝肾功能恶化、腹泻、恶心呕吐、肌痛、胸闷等副作用,康复良好出院。

结论

该病例提示,肾功能不全的百岁老人可谨慎使用帕罗韦德,核酸持续阳性的患者可考虑两个疗程的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/1bfe65bb3837/WJR-16-489-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/467f7ab5ff96/WJR-16-489-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/ec427660842a/WJR-16-489-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/84ed286c35a4/WJR-16-489-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/1731cbbd81bd/WJR-16-489-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/f50ac3f3b690/WJR-16-489-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/1bfe65bb3837/WJR-16-489-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/467f7ab5ff96/WJR-16-489-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/ec427660842a/WJR-16-489-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/84ed286c35a4/WJR-16-489-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/1731cbbd81bd/WJR-16-489-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/f50ac3f3b690/WJR-16-489-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c94b/11440271/1bfe65bb3837/WJR-16-489-g006.jpg

相似文献

1
Prolonged course of Paxlovid administration in a centenarian with COVID-19: A case report.一名百岁COVID-19患者长期服用帕罗韦德的病例报告。
World J Radiol. 2024 Sep 28;16(9):489-496. doi: 10.4329/wjr.v16.i9.489.
2
Paxlovid administration in elderly patient with COVID-19 caused by Omicron BA.2.0: A case report.奥密克戎 BA.2 引起的 COVID-19 老年患者使用帕罗韦德治疗:一例报告。
Medicine (Baltimore). 2022 Nov 11;101(45):e31361. doi: 10.1097/MD.0000000000031361.
3
Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial.帕罗韦德对感染 SARS-CoV-2 奥密克戎变异株的成年患者住院结局和新冠后状况的影响:一项非随机对照临床试验。
Medicine (Baltimore). 2023 Dec 22;102(51):e36714. doi: 10.1097/MD.0000000000036714.
4
[COVID-19 treated with oral Nirmatrelvir-Ritonavir in 3 children].3例儿童口服奈玛特韦-利托那韦治疗新型冠状病毒肺炎
Zhonghua Er Ke Za Zhi. 2022 Nov 2;60(11):1168-1171. doi: 10.3760/cma.j.cn112140-20220701-00608.
5
[Clinical analysis of the first patient with imported Middle East respiratory syndrome in China].[中国首例输入性中东呼吸综合征患者临床分析]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Aug;27(8):630-4. doi: 10.3760/cma.j.issn.2095-4352.2015.08.002.
6
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.加利福尼亚州 2021 年 12 月至 2022 年 5 月辉瑞公司新冠口服药 Paxlovid 治疗后因 COVID-19 住院和急诊就诊情况。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
7
Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.化湿败毒颗粒联合奈玛特韦片/利托那韦片组合药物治疗奥密克戎(B.1.1.529)感染高风险因素患者的有效性和安全性:一项多臂、单中心、开放性、随机对照临床试验。
Phytomedicine. 2023 Nov;120:155025. doi: 10.1016/j.phymed.2023.155025. Epub 2023 Aug 16.
8
Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations.延长疗程的口服奈玛特韦/利托那韦(帕罗韦德)对确诊的新冠后综合征的影响:病例系列及研究考量
Res Sq. 2023 Sep 20:rs.3.rs-3359429. doi: 10.21203/rs.3.rs-3359429/v1.
9
SARSCoV2 Omicron BA.5 infection recurrence after Paxlovid treatment: The first case report in Hunan Province.湖南省首例帕罗韦德治疗后 SARSCoV2 奥密克戎 BA.5 感染复发。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Dec 28;47(12):1775-1780. doi: 10.11817/j.issn.1672-7347.2022.220413.
10
Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature.普克鲁胺治疗帕罗韦德治疗后 COVID-19 反弹:四例报告及文献复习。
J Clin Lab Anal. 2023 Apr;37(7):e24880. doi: 10.1002/jcla.24880. Epub 2023 Apr 23.

本文引用的文献

1
Weakened humoral and cellular immune response to the inactivated COVID-19 vaccines in Chinese individuals with obesity/overweight.中国肥胖/超重个体对新冠病毒灭活疫苗的体液免疫和细胞免疫反应减弱。
Genes Dis. 2023 Mar;10(2):608-617. doi: 10.1016/j.gendis.2022.10.023. Epub 2022 Nov 29.
2
Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave.上海奥密克戎变异株流行期间老年人发生严重 COVID-19 结局的老年风险和保护因素。
Emerg Microbes Infect. 2022 Dec;11(1):2045-2054. doi: 10.1080/22221751.2022.2109517.
3
Efficacy of COVID-19 treatments among geriatric patients: a systematic review.
老年患者中新冠病毒疾病治疗方法的疗效:一项系统综述
Ther Adv Infect Dis. 2022 Jun 1;9:20499361221095666. doi: 10.1177/20499361221095666. eCollection 2022 Jan-Dec.
4
Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.帕克洛维德降低高危患者的严重 2019 冠状病毒病和死亡率的有效性。
Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443.
5
Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022.COVID-19 mRNA 疫苗接种在预防既往 SARS-CoV-2 感染成年人 COVID-19 相关住院方面的有效性-美国,2021 年 6 月-2022 年 2 月。
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):549-555. doi: 10.15585/mmwr.mm7115e2.
6
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
7
Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M inhibitor in animal models.在动物模型中,口服 SARS-CoV-2 M 抑制剂奈玛特韦(PF-07321332)的生殖和发育安全性。
Reprod Toxicol. 2022 Mar;108:56-61. doi: 10.1016/j.reprotox.2022.01.006. Epub 2022 Jan 31.
8
Molnupiravir in COVID-19: A systematic review of literature.莫努匹韦治疗 COVID-19:文献系统评价。
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30.
9
Coping With COVID-19: Health Risk Communication and Vulnerable Groups.应对新冠疫情:健康风险沟通与弱势群体
Disaster Med Public Health Prep. 2021 Jul 12;17:e22. doi: 10.1017/dmp.2021.225.
10
Dialysis-Induced Immune Dysregulations and Their Possible Impacts on COVID-19.透析引起的免疫失调及其对 COVID-19 的可能影响。
Iran J Kidney Dis. 2021 May;15(3):161-167.